BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 16235577)

  • 21. Clinical trials: a recent emphasis in the prevention program of the National Cancer Institute.
    DeWys WD; Greenwald P
    Semin Oncol; 1983 Sep; 10(3):360-4. PubMed ID: 6665563
    [No Abstract]   [Full Text] [Related]  

  • 22. Annual meeting of the New Clinical Drug Evaluation Units (NCDEU) program, Psychopharmacology Research Branch, National Institute of Mental Health, 23-25 May 1978, Key Biscayne, Florida.
    Psychopharmacol Bull; 1979 Jul; 15(3):22-44. PubMed ID: 493456
    [No Abstract]   [Full Text] [Related]  

  • 23. [Models and methods used for the selection of antitumor preparations in the USSR and abroad].
    Sof'ina ZP
    Vopr Onkol; 1976; 22(4):82-96. PubMed ID: 1274284
    [No Abstract]   [Full Text] [Related]  

  • 24. Technology transfer from biomedical research to clinical practice: measuring innovation performance.
    Balas EA; Elkin PL
    Eval Health Prof; 2013 Dec; 36(4):505-17. PubMed ID: 24142938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical research programs in vision: The National Eye Institute perspective.
    Goldberg IA
    Am J Optom Physiol Opt; 1981 Apr; 58(4):270-6. PubMed ID: 7282850
    [No Abstract]   [Full Text] [Related]  

  • 26. Despite research, FDA says marijuana has no benefit.
    Twombly R
    J Natl Cancer Inst; 2006 Jul; 98(13):888-9. PubMed ID: 16818851
    [No Abstract]   [Full Text] [Related]  

  • 27. The National Institute of General Medical Sciences.
    Becker GJ
    J Am Coll Radiol; 2005 Sep; 2(9):790-2. PubMed ID: 17411928
    [No Abstract]   [Full Text] [Related]  

  • 28. Orphan products activities of the National Institutes of Health.
    Schepartz SA
    Prog Clin Biol Res; 1983; 127():173-86. PubMed ID: 6889399
    [No Abstract]   [Full Text] [Related]  

  • 29. Historical background of the National Cancer Institute's drug development thrust.
    Zubrod CG; Schepartz SA; Carter SK
    Natl Cancer Inst Monogr; 1977 Mar; (45):7-11. PubMed ID: 337156
    [No Abstract]   [Full Text] [Related]  

  • 30. Medicine. A portfolio model of drug development for tuberculosis.
    Glickman SW; Rasiel EB; Hamilton CD; Kubataev A; Schulman KA
    Science; 2006 Mar; 311(5765):1246-7. PubMed ID: 16513969
    [No Abstract]   [Full Text] [Related]  

  • 31. Innovation meets quality: moving cellular therapies at the National Institutes for Health from bench to bedside.
    Read EJ
    Cytotherapy; 2004; 6(6):626-8. PubMed ID: 15764029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Complementary and alternative medicine: the road less traveled?
    Caplan C; Griffin K
    Issue Brief (Public Policy Inst (Am Assoc Retired Pers)); 2000 Nov; (IB46):1-14. PubMed ID: 11885592
    [No Abstract]   [Full Text] [Related]  

  • 33. New office and new leader aim to streamline FDA cancer drug review process.
    Twombly R
    J Natl Cancer Inst; 2005 May; 97(10):708-9. PubMed ID: 15900036
    [No Abstract]   [Full Text] [Related]  

  • 34. Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
    Edwards S
    Find Brief; 2005 Jan; 8(1):1-3. PubMed ID: 15672527
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical research. No lifeline for proposed breast cancer prevention trial.
    Kaiser J
    Science; 2007 Jun; 316(5832):1679. PubMed ID: 17588904
    [No Abstract]   [Full Text] [Related]  

  • 36. Who shall live? The tribulations of clinical trials.
    Small WE
    Am Pharm; 1979 May; 19(5):10-2. PubMed ID: 382813
    [No Abstract]   [Full Text] [Related]  

  • 37. Stat bite: Treatment trials in the PDQ clinical trials database, by phase.
    J Natl Cancer Inst; 2004 Sep; 96(18):1355. PubMed ID: 15367566
    [No Abstract]   [Full Text] [Related]  

  • 38. Laetrilomania--again.
    Relman AS
    N Engl J Med; 1978 Jan; 298(4):215-6. PubMed ID: 339088
    [No Abstract]   [Full Text] [Related]  

  • 39. Complementary and alternative medicine. Considering the alternatives.
    Weber DO
    Physician Exec; 1998; 24(6):6-14. PubMed ID: 10351720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Report of the Cancer Chemotherapy Collaborative Program Review Committee: the Richardson report. June 1966, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
    Cancer Treat Rep; 1984 Jan; 68(1):343-56. PubMed ID: 6692435
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.